We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Public Pressure Ends 'Bundled' Drug Program, But How Much Cost Will Drop Remains Unclear.
- Authors
Cotton, Paul
- Abstract
Reports on the decision of Sandoz Pharmaceuticals Corp. to reduce the cost of its schizophrenia drug clozapine due to pressure of antitrust suits and acts of the U.S. Congress in 1991. Reason for the exclusion of the drug from many state Medicaid programs; Comments from health executives on the reduction of the cost of the drug; Information on the Clozapine Patient Monitoring System.
- Subjects
SANDOZ Pharmaceutical Corp.; CLOZAPINE; DRUG prices; ANTITRUST law; SCHIZOPHRENIA
- Publication
JAMA: Journal of the American Medical Association, 1991, Vol 265, Issue 7, p837
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.1991.03460070015004